A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

NCT04361279 PHASE3 COMPLETED

This is a randomised, double-blind, positive drug parallel controlled equivalence clinical trial initiated at about 30 sites in China. In the trial, it is planned to enroll 414 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.

Details

Lead sponsor	Shanghai Institute Of Biological Products
Phase	PHASE3
Status	COMPLETED
Enrolment	421
Start date	Thu Jul 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diffuse Large B-Cell Lymphoma

Interventions

• SIBP-02
• Rituximab

Countries

China